Preoperative AFU Is a Useful Serological Prognostic Predictor for Colorectal Liver Oligometastasis Patients Undergoing Hepatic Resection

Deng, Yuxiang; Zhao, Yujie; Fan, Wenhua; Peng, Jianhong; Luo, Xiao; Mo, Yiwen; Xiao, Binyi; Zhang, Lin; Pan, Zhizhong

doi:10.7150/jca.31539

Cited by 6 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to previous research, NLN count at the time of lymphadenectomy may have a distinct effect on patient survival (27)(28)(29). Therefore, in the current study, the optimal cutoff value for NLN count was identified using X-tile software, which has been used in other studies (29,30). These results found the optimal cutoff value for NLN count to be 13 in nonmetastatic patients, with patients with a count of 13 or more than 13 at NLN dissection had significantly better CSS than those with less than 13.…”

Section: Discussionmentioning

confidence: 99%

The prognostic factors of primary colorectal sarcoma and the clinical outcomes of negative lymph node dissection

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The prognostic factors of primary colorectal sarcoma and the clinical outcomes of negative lymph node dissection

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Serum tumor markers play important roles in the diagnosis, prognostic prediction and recurrence monitoring of gastrointestinal malignancies. As studies have suggested, AFU was considered to be related to liver metastasis in colorectal cancer [ 4 ]; AFP was associated with prognosis in gastric cancer patients undergoing surgery alone [ 5 ]; preoperative CEA could predict the prognosis of GC patients with no lymph node metastasis [ 6 ]; CA199 was an independent prognostic factor in gastroesophageal junction (GEJ) cancer patients who experienced surgery alone [ 7 ]; the CA125 level was related to the degree of peritoneal dissemination and the existence of malignant ascites in GC patients with peritoneal metastasis [ 8 ]; and CA724 was correlated with pTNM stage in gastric carcinoma patients [ 9 ]. However, for GC patients who underwent NCT, the evidence of these markers is still insufficient.…”

Section: Introductionmentioning

confidence: 99%

CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy

et al. 2021

View full text Add to dashboard Cite

Background Serum tumor markers including AFU, AFP, CEA, CA199, CA125 and CA724, are of great importance in the diagnosis, prognostic prediction and recurrence monitoring of gastrointestinal malignancies. However, their significance in gastric cancer (GC) patients with neoadjuvant therapy (NCT) is still uncertain. The aim of this study was to evaluate the predictive value of these six tumor markers in locally advanced GC patients who underwent NCT and curative surgery. Methods In total, 290 locally advanced GC patients who underwent NCT and D2 radical gastrectomy were retrospectively analyzed. Data on their tumor markers before (pre-) and after (post-) NCT and pathological characteristics were extracted from the database of our hospital. The optimal cutoff values of the six tumor markers were calculated by the ROC curve and Youden index. Their predictive significance was analyzed and survival curves for overall survival (OS) were obtained by the Kaplan-Meier method. Associations between categorical variables were explored by the chi-square test or Fisher’s exact test. Multivariate analyses were performed by the Cox regression model. Results Pre- and post-CA199, −CA125 and -CA724 could predict overall survival (all P < 0.05), but only the change (diff-) of CA199 was related to prognosis (P = 0.05). In the multivariable analysis, pre- (P = 0.014) and post-CA724 (P = 0.036) remained significant, though diff-CA724 was not an independent prognostic factor (P = 0.581). In addition, pre- and post-CA199, −CA125 and -CA724 were associated with lymph node metastasis (N- vs N+) and pathological stage (I-II vs III) (all P < 0.05). Moreover, post-CA724 was related to the vascular or lymphatic invasion (P = 0.019), while pre-CA724 was not (P = 0.082). However, AFU, AFP and CEA showed no association with survival (P > 0.05). Conclusions CA724 is an independent factor for prognosis and could be used to predict ypN and ypTNM stage in locally advanced GC patients undergoing NCT and curative resection.

show abstract

“…Serum tumor markers play important roles in the diagnosis, prognostic prediction and recurrence monitoring of gastrointestinal malignancies. As studies have suggested, AFU was considered to be related to liver metastasis in colorectal cancer [4]; AFP was associated with prognosis in gastric cancer patients undergoing surgery alone [5]; preoperative CEA could predict the prognosis of GC patients with no lymph node metastasis [6]; CA199 was an independent prognostic factor in gastroesophageal junction (GEJ) cancer patients who experienced surgery alone [7]; the CA125 level was related to the degree of peritoneal dissemination and the existence of malignant ascites in GC patients with peritoneal metastasis [8]; and CA724 was correlated with pTNM stage in gastric carcinoma patients [9]. However, for GC patients who underwent NCT, the evidence of these markers is still insu cient.…”

Section: Introductionmentioning

confidence: 99%

CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy

Tong

Zhao

Shan

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Serum tumor markers including AFU, AFP, CEA, CA199, CA125 and CA724, are of great importance in the diagnosis, prognostic prediction and recurrence monitoring of gastrointestinal malignancies. However, their significance in gastric cancer (GC) patients with neoadjuvant therapy (NCT) is still uncertain. The aim of this study was to evaluate the predictive value of these six tumor markers in locally advanced GC patients who underwent NCT and curative surgery. Methods: In total, 290 locally advanced GC patients who underwent NCT and D2 radical gastrectomy were retrospectively analyzed. Data on their tumor markers before (pre-) and after (post-) NCT and pathological characteristics were extracted from the database of our hospital. The optimal cutoff values of the six tumor markers were calculated by the ROC curve and Youden index. Their predictive significance was analyzed and survival curves for overall survival (OS) were obtained by the Kaplan-Meier method. Associations between categorical variables were explored by the chi-square test or Fisher's exact test. Multivariate analyses were performed by the Cox regression model. Results: Pre- and post-CA199, -CA125 and -CA724 could predict overall survival (all P < 0.05), but only the change (diff-) of CA199 was related to prognosis (P = 0.05). In the multivariable analysis, pre- (P = 0.014) and post-CA724 (P = 0.036) remained significant, though diff-CA724 was not an independent prognostic factor (P = 0.581). In addition, pre- and post-CA199, -CA125 and -CA724 were associated with lymph node metastasis (N- vs N+) and pathological stage (Ⅰ-Ⅱ vs Ⅲ) (all P < 0.05). Moreover, post-CA724 was related to the vascular or lymphatic invasion (P = 0.019), while pre-CA724 was not (P = 0.082). However, AFU, AFP and CEA showed no association with survival (P > 0.05). Conclusions: CA724 is an independent factor for prognosis and could be used to predict ypN and ypTNM stage in locally advanced GC patients undergoing NCT and curative resection.

show abstract

Preoperative AFU Is a Useful Serological Prognostic Predictor for Colorectal Liver Oligometastasis Patients Undergoing Hepatic Resection

Cited by 6 publications

References 36 publications

The prognostic factors of primary colorectal sarcoma and the clinical outcomes of negative lymph node dissection

The prognostic factors of primary colorectal sarcoma and the clinical outcomes of negative lymph node dissection

CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy

CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy

Contact Info

Product

Resources

About